Research

Hormonal

Semaglutide 2.4 mg is a cost-effective treatment for obesity and overweight in the US, providing greater weight loss and QALYs than diet/exercise, no treatment, or other anti-obesity medications, provided the willingness-to-pay threshold is $150,000 per QALY.

For patients with obesity or overweight plus comorbidities, semaglutide 2.4 mg combined with diet and exercise is a cost-effective medical option in the US, offering significant weight loss and quality-adjusted life years compared to lifestyle changes alone or other medications, assuming a willingness-to-pay threshold of $150,000 per QALY.

GoodSupportsHIGH confidence
Under a willingness-to-pay threshold of $150,000, semaglutide 2.4 mg was estimated to be cost-effective compared with no treatment, diet and exercise, and anti-obesity medications over a 30-year horizon.
Nina Kim et al. · Journal of Managed Care & Specialty Pharmacy · 2022

Why this rating

Based on a Markov model using data from pivotal Phase 3 trials (STEP 1, 2, 4) and real-world evidence, though it is an economic model rather than a direct clinical trial.

Source

Cost-effectiveness analysis of semaglutide 2.4 mg for the treatment of adult patients with overweight and obesity in the United States

Nina Kim et al. · Journal of Managed Care & Specialty Pharmacy · 2022

DOI 10.18553/jmcp.2022.28.7.740

economic_modelCited 76×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →